No Detail Found!

Systemic Immune In ammation Index as a Key Marker of Survival and Immune-related Adverse Events in Immune Checkpoint Inhibitor Therapy

Author(s)
Ferhat Ekinci Department of Medical Oncology, Manisa Celal Bayar University, Manisa, Turkey
Onur Yazdan Balcik Department of Medical Oncology, Aydin Adnan Menderes University, Aydin, Turkey
Bilgin Demir Department of Medical Oncology, Aydin Adnan Menderes University, Aydin, Turkey
Pinar Gursoy Department of Medical Oncology, Ege University, Izmir, Turkey
Ahmet Ozveren Department of Medical Oncology, Izmir Kent Hospital, Izmir, Turkey
Atike Pinar Erdogan Department of Medical Oncology, Manisa Celal Bayar University, Manisa, Turkey
Abstract
Objective: To evaluate the prognostic signi cance of the new index designed by formulating neutrophil, lymphocyte, and platelet counts in patients with metastatic disease receiving immune checkpoint inhibitors (ICI) and its e ect on theimmune-related adverse events (irAEs). Study Design: Cohort study. Place and Duration of Study: Department of Medical Oncology, University of Manisa Celal Bayar, University of Aydin Adnan Menderes, and University of Ege, and Izmir Kent Hospital, Turkey, from January 2016 to April 2020. Methodology: Patients with metastatic disease receiving ICI su cient follow-up data were included. Patients, who had received treatment for a minimum of 3 months, were evaluated for the responseS.ystemic immune-in ammation index (SII) was calculated as neutrophil (/L) × (lymphocyte (/L) / platelet (/LT).he cut-o value was determined by examining the area under the receiver operating characteristic (ROC) curve for the SII value. The endpoints of this study included overall survival (OS) and progression-free survival (PFS). Results: A total of 168, patients who received ICI in the metastatic stage, were evaluated.The OS of the patients with low SII scores was 110.8 months (95% CI, 88.2-133.5), while patients with high SII scores were 36.0 months (95% CI, 28.4-43.6) and reached statistical signi cance (p <0.001). The results ofunivariate (HR=3.376, 95% CI, 1.986-5.739, p<0.001 and multivariate (HR=2.792, 95% CI, 1.495-5.215, p=0.011) analyses were statistically signi cant as well. Conclusion: The SII score in patients with metastatic disease receiving ICI was closely related to the prognosis. Patients with a high SII score are associated with a worse prognosis, these patients develop fewer irAEs.
Publication Details
Page(s) 996-1003
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 32, Issue: 8, Year: 2022

Request the full text from PASTIC

Keywords
Overall survival, Progression-free survival, Nivolumab, Systemic immune in ammation index, 0mmune checkpoint inhibitor, Pembrolizumab
0

Citations

0

Downloads

82

Views